Abstract:Farnesoid X receptor (FXR) is a promising target for drug discovery against nonalcoholic fatty liver disease (NAFLD). However, no FXR agonist has been approved for NAFLD so far. The R & D of FXR agonists are somewhat hindered by the lack of effective and safe chemotypes. To this end, we developed a multi-stage computational workflow to screen the Specs and ChemDiv chemical library for FXR agonists, which consisted of machine learning (ML)-based classifiers, shape-based and electrostatic-based models, a FRED-based molecular docking protocol, an ADMET prediction protocol and substructure search. As a result, we identified a novel chemotype that has never been reported before, with compound XJ02862 (ChemDiv ID: Y020-6413) as the representative. By designing an asymmetric synthesis strategy, we were able to prepare four isomers of compound XJ02862. Interestingly, one of the isomers, 2-((S)-1-((2S,4R)-2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl)-1-oxopropan-2-yl)hexahydro-1H-isoindole-1,3(2H)-dione (XJ02862-S2), showed potent FXR agonistic activity in HEK293T cells. The molecular docking, molecular dynamics simulations and site-directed mutagenesis suggested the hydrogen bond between compound XJ02862-S2 and HIS294 of FXR is essential for ligand binding. We further demonstrated that compound XJ02862-S2 had no agonistic effect on TGR5. Further biological experiments have shown that compound XJ02862-S2 could ameliorate hypercholesterolemia, hepatic steatosis, hyperglycemia, insulin resistance (IR) in high-fat-diet induced obese (DIO) mice. In term of molecular mechanism, compound XJ02862-S2 regulates the expression of FXR downstream genes involved in lipogenesis, cholesterol transport and bile acid biosynthesis and transport. Taken together, we have discovered a novel chemotype as potent FXR agonists for NAFLD by computational modeling, chemical synthesis and biological evaluation.

Predicting selective liver X receptor β agonists using multiple machine learning methods.

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Identifying farnesoid X receptor agonists by naïve Bayesian and recursive partitioning approaches

A De Novo Substructure Generation Algorithm for Identifying the Privileged Chemical Fragments of Liver X Receptorβ Agonists

Three-Dimensional Pharmacophore Modeling of Liver-X Receptor Agonists

Prediction of Farnesoid X Receptor Disruptors with Machine Learning Methods.

In silico prediction of pregnane X receptor activators by machine learning approaches.

Structurally Selective Mechanism of Liver X Receptor Ligand: in Silico and in Vitro Studies.

Activity Prediction of Hormone-Sensitive Lipase Inhibitors Based on Machine Learning Methods

Discovery of New LXRβ Agonists As Glioblastoma Inhibitors.

Identify Liver X Receptor Β Modulator Building Blocks by Developing a Fluorescence Polarization-Based Competition Assay.

In Silico Identification of Small Molecules As Novel LXR Agonists for the Treatment of Cardiovascular Disease and Cancer

Prediction of Orthosteric and Allosteric Regulations on Cannabinoid Receptors Using Supervised Machine Learning Classifiers.

LASSO-ing Potential Nuclear Receptor Agonists and Antagonists: A New Computational Method for Database Screening

Discriminating Functional and Non-Functional Nuclear-Receptor Ligands with a Conformational Selection-Inspired Machine Learning Algorithm

Identification of Pharmacophoric Fragments of DYRK1A Inhibitors Using Machine Learning Classification Models

Enhancing Multi-species Liver Microsomal Stability Prediction through Artificial Intelligence

Identification of A Novel Partial Agonist of Liver X Receptor Alpha (lxr Alpha) Via Screening

Prediction of Estrogen Receptor Agonists and Characterization of Associated Molecular Descriptors by Statistical Learning Methods.

Virtual Screening and Experimental Validation Identify Novel Modulators of Nuclear Receptor RXRα from Drugbank Database.

Discovery of Tissue Selective Liver X Receptor Agonists for the Treatment of Atherosclerosis Without Causing Hepatic Lipogenesis.